Effects of kombucha consumption on well-being, induced stress, and inflammatio

Not Applicable

• Conditions: Inflammation and well-being; Not Applicable

• Registration Number: ISRCTN70525386
• Lead Sponsor: Aberystwyth University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2024-03-06
• Last Update Posted: 18 March 2024
• Study Completion: 2025-02-28

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. Subjects over 18 years of age and under 60 years of age
2. Subjects who are able to commit to multiple visits to WARU
3. Subjects who can provide venous blood samples, urine samples, and saliva samples
4. Subjects able to provide written informed consent prior to performing any study procedures

Exclusion Criteria

1. Subjects with a diagnosis of Alzheimer’s disease or other forms of dementia
2. Subjects taking medication for the treatment of dementia (such as acetylcholinesterase inhibitors (Aricept, Excelon), memantine (Namenda) or other medications with similar mechanisms of action) or medical foods (such as Cerefolin, Souvenaid, Axona) for the treatment of dementia.
3. Subjects who are pregnant or lactating
4. Subjects with medical condition or disease that is life-threatening
5. Subjects diagnosed with diabetes.
6. Subjects already consuming pro-biotics who will not comply with the 4-week washout
7. Subjects with any cardiovascular diseases
8. Subjects with severe physical illnesses (e.g., fibromyalgia)
9. Subjects experiencing hypertension (high blood pressure)
10. Subjects with endocrine disorders
11. Subjects suffering from substance abuse
12. Subjects who heavily smoke (>10 cigarettes/day)
13. Any medication known to affect the HPA axis.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Quality of life is measured by the EuroQol -5D-5L at baseline and after 8 weeks